Ask AI

Interactive Decision Support Tool: Expert Treatment Guidance for Metastatic Castration Resistant Prostate Cancer

Tool
Tool
This activity is available for 0.25 CME/CE credit(s).

Released: October 15, 2025

Expiration: April 14, 2026

See Activity Collection

Access this Interactive Decision Support Tool on selecting optimal therapy for patients with metastatic castration resistant prostate cancer, including expert’s decision-making criteria for selecting patients eligible for radioligand therapies among other key considerations.

mCRPC Decision Support Tool

With just a few clicks, get expert treatment recommendations for your patient with metastatic castration resistant prostate cancer.

To begin, answer a few quick questions below about your actual or hypothetical patient. Then, we’ll show how your approach compares with the expert panel’s.

Interactive Decision Support Tool

Program Content